• Ulcerative colitis
  • Crohn’s disease treatments

Inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis (UC) are lifelong conditions with unknown aetiology that are primarily diagnosed in younger patients.

Incidence of these conditions continues to rise within the community. With the increased prevalence and severity of the disease, patients are being offered more complex drug treatments that are required to manage their symptoms. 

These drug treatments are not always suitable for all IBD patients due to side effects, failure to respond, loss of response and each individual’s disease being unique to them.

This leads to the requirement for trialling new and innovative IBD treatments that are safe, effective and will help improve patient remission rates in the long term.

St John of God Subiaco Hospital cares for over 1,000 patients with IBD who are managed by multiple gastroenterologists and the highly qualified IBD team.

There are currently five active clinical trials at St John of God Subiaco Hospital - three are for UC patients and two are for Crohn’s disease patients.

St John of God Subiaco Hospital was the first site in Australia to recruit a participant to the UC study, Quasar CNTO1959UCO3001. This participant is still active in the study and is happy to continue.

The SER-301-001 UC study has sparked interest with the IBD team due to the newly designed investigational product using an Encapsulated Cultivated Multi-Strain Live Bacterial Biotherapeutic to target the gut microbiome. 

Prof Ian Lawrance 


Dr Siva Pulusu 

IBD Team
Jill Philpott 
Clarizze Abello
Janelle Leadbitter
Julie Smallpage
Dr Angela Baird
Stephanie Austin

1. Mashtoub, S., Chartier, L. C., Trinder, D., Lawrance, I. C., & Howarth, G. S. (2021). Emu Oil Attenuates Disease Severity and Results in Fewer Large Colonic Tumours in a Mouse Model of Colitis-Associated Colorectal Cancer. Nutrition and Cancer. https://doi.org/10.1080/01635581.2021.1909737

2. Julsgaard, M., Hvas, C. L., Gearry, R. B., Gibson, P. R., Fallingborg, J., Sparrow, M. P., Bibby, B. M., Connell, W. R., Brown, S. J., Kamm, M. A., Lawrance, I. C., Vestergaard, T., Svenningsen, L., Baekdal, M., Kammerlander, H., Walsh, A., Boysen, T., Bampton, P., Radford-Smith, G., ... Bell, S. J. (2020). Anti-TNF Therapy in Pregnant Women with Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflammatory Bowel Diseases, 26(1), 93-102. https://doi.org/10.1093/ibd/izz110

3. Mitchell, C. J., Howarth, G. S., Chartier, L. C., Trinder, D., Lawrance, I. C., Huang, L. S., & Mashtoub, S. (2020). Orally administered emu oil attenuates disease in a mouse model of Crohn’s-like colitis. Experimental Biology and Medicine, 245(18), 1697-1707. https://doi.org/10.1177/1535370220951105

4. Pulusu, S. S. R., Srinivasan, A., Krishnaprasad, K., Cheng, D., Begun, J., Keung, C., van Langenberg, D., Thin, L., Mogilevski, T., De Cruz, P., Radford-Smith, G., Flanagan, E., Bell, S., Kashkooli, S., Sparrow, M.P., Ghaly, S., Bampton, P. A., Sawyer, E., Connor, S., ... Lawrance, I. (2020). Vedolizumab for ulcerative colitis: Real world outcomes from a multicentre observational cohort of Australia and Oxford. World Journal of Gastroenterology, 26(30), 4428-4441. https://doi.org/10.3748/WJG.V26.I30.4428